In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 6, 2004, Pages 330-339

  Tibbles, Heather E ^a,b   Samuel, Peter ^a,b   Erbeck, Doug ^a,b   Mahajan, Sandeep ^a,b   Uckun, Fatih M ^c  

^a Paradigm Pharmaceuticals   (United States)

^b Department of Hematology ^*  (United States)

^c PARKER HUGHES INSTITUTE   (United States)

Author keywords

Antileukemic agent; CAS 244240 24 2; LFM A13, antithrombotic profile, in vivo toxicity, oral formulation; Thromboembolism, experimental; Cyano hydroxy methyl N (2,5 dibromophenyl) propenamide

Indexed keywords

ANTICOAGULANT AGENT; DIPYRIDAMOLE; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; LEUKEMIA; MOUSE; NONHUMAN; RISK; THROMBOEMBOLISM;

EID: 3042739756     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296980     Document Type: Article

References (30)

1. Globecan, Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, IARC Press, Lyon (2001)
2. Uckun, F. M., Treating Chronic Leukemias. Minnesota Physician. 16, 14 (2002)
3. [31 Uckun, F. M., Zheng, Y., Cetkovic-Cvrlje, M. et al., In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin. Cancer Res. 8, 1224 (2002)
4. Heerema, N. A., Sather, H. N., Sensel, M. G. et al., Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18, 3837 (2000)
5. Mitchell, L. G., A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 97, 508 (2003)
6. Karthaus, M., Doellmann, T., Klimasch, T. et al., Central venous catheter infections in patients with acute leukemia. Chemotherapy 48, 154 (2002)
7. Otten, T. R., Stein, P. D., Patel, K. C. et al., Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 123, 809 (2003)
8. Gomes, M. P., Deitcher, S. R., Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt). 17, 126, 139; discussion 139-44 (2003)
9. Mahajan, S., Ghosh, S., Sudbeck, E. A. et al., Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl) propenamide]. J. Biol Chem. 274, 9587 (1999)
10. Dibirdik, I., Bofenkamp, M., Skeben, P. et al., Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields. Leuk. Lymphoma 40, 149 (2000)
11. Ghosh, S. and Uckun, F. M., Alpha-cyano-N-(2,5-dibromophenyl)-beta- hydroxybut-2-enamide. Acta Crystallogr. C 55, 1364 (1999)
12. Ghosh, S., Jennissen, J. D., Zheng, Y. et al., Three leflunomide metabolite analogs. Acta Crystallogr. C 56, 1254 (2000)
13. Goodman, P. A., Niehoff, L. B., Uckun, F. M., Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells. J. Biol. Chem. 273, 17742 (1998)
14. Heinonen, J. E., Smith, C. I., and Nore, B. F., Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 527, 274 (2002)
15. Kristupaitis, D., Dibirdik, I., Vassilev, A. et al., Electromagnetic field-induced stimulation of Bruton's tyrosine kinase. J. Biol. Chem. 273, 12397 (1998)
16. Mahajan, S., Vassilev, A., Sun, N. et al., Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J. Biol. Chem. 276, 31216 (2001)
17. Malaviya, R., Vassilev, A., and Uckun, F. M., 2,4,6-Trihydroxy-alpha-p- methoxyphenylacetophenone (Compound D-58) is a potent inhibitor of allergic reactions. Am J. Ther. 8, 417 (2001)
18. Mao, C., Zhou, M., and Uckun, F. M., Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J. Biol. Chem. 276, 41435 (2001)
19. Sudbeck, E. A., Liu, X. P., Narla, R. K. et al., Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5, 1569 (1999)
20. Uckun, F. M., Vassilev, A. O., Bartell, S. et al., The Anti-leukemic Bruton's Tyrosine Kinase Inhibitor LFM-A13 Prevents Fatal Thromboembolism. Leuk. Lymphoma. 44, 1569 (2003)
21. [211 Tibbles, H., Vassilev, A., Uckun, F. M., A dual function anti-leukemic agent with anti-thrombotic activity. Leuk. Lymphoma 43, 1121 (2002)
22. Uckun, F. M., Waddick, K. G., Mahajan, S. et al., BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science 273, 1096 (1996)
23. Uckun, F. M., Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem. Pharmacol. 56, 683 (1998)
24. Uckun, F. M., Sudbeck, E. A., Mao, C. et al., Structure-based design of novel anticancer agents. Curr. Cancer Drug Targets 1, 59 (2001)
25. Uckun, F. M., Rationally designed anti-mitotic agents with pro-apoptotic activity. Curr. Pharm. Res. 7, 1627 (2001)
26. Vassilev, A., Ozer, Z., Navara, C. et al., Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J. Biol. Chem. 274, 1646 (1999)
27. Zhu, D. M., Narla, R. K., Fang, W. H. et al., Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin. Cancer Res. 4, 2967 (1998)
28. Zhu, D. M., Uckun, F. M., Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. Clin. Cancer Res. 6, 2456 (2000)
29. Zhu, D. M., Tibbles, H. E., Vassilev, A. O. et al., SYK and LYN mediate B-cell receptor-independent calcium-induced apoptosis in DT-40 lymphoma B-cells. Leuk. Lymphoma 43, 2165 (2002)
30. Harkness, J. E. and Wagner, J. E., The biology and medicine of rabbits and rodents, 3rd ed., Lea & Febiger, Philadelphia (1989)